Polymixin in oncology clinical practice
Дмитриева Н. В., Петюхова И. Н., Григориевскайа З. В., Багирова Н. С., Терешченко И. В., Григориевскy Е. Д.
Сибирский онкологический журнал
Т. 17, Вып. 3, С. 88-93
Опубликовано: 2018
Тип ресурса: Статья
DOI:10.21294/1814-4861-2018-17-3-88-93
Аннотация:
The purpose of the study was to present data on polymixin-based antibiotics with activity against infections caused by multidrug-resistant Gram-negative bacteria, such as Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Material and methods. The review includes data from clinical as well as in vitro studies for the period 1998–2017. The search for relevant sources was carried out in the Medline, Cochrane Library, Elibrary and other databases. Results. The analysis of the data showed the presence of synergism and additive activity of polymyxin in combination with carbapenems, rifampicin and azithromycin. However, experimental data showed no direct positive correlation between combination of polymyxim and azithromycin/ rifampicin. In clinical studies, in hospital-acquired pneumonia, including ventilator-associated pneumonia, the clinical response rate of polymyxin B combined with other antibiotics ranged from 38 [%] to 88 [%]. High nephro- and neurotoxicity of poly
Ключевые слова:
Acinetobacter baumannii; Cancer patients; Gram-negative bacteria; Klebsiella pneumoniae; Multidrug resistance; Polymyxin B; Pseudomonas aeruginosa
Язык текста: Русский
ISSN: 2312-3168
Дмитриева Н. В.
Петюхова И. Н.
Григориевскайа З. В.
Багирова Н. С.
Терешченко И. В.
Григориевскy Е. Д.
Dmitrieva N. V.
Petukhova I. N.
Grigorievskaya Z. V.
Bagirova N. S.
Tereshchenko I. V.
Grigorievsky E. D.
Polymixin in oncology clinical practice
Текст визуальный непосредственный
Сибирский онкологический журнал
Томский национальный исследовательский медицинский центр РАН
Т. 17, Вып. 3 С. 88-93
2018
Статья
Acinetobacter baumannii Cancer patients Gram-negative bacteria Klebsiella pneumoniae Multidrug resistance Polymyxin B Pseudomonas aeruginosa
The purpose of the study was to present data on polymixin-based antibiotics with activity against infections caused by multidrug-resistant Gram-negative bacteria, such as Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Material and methods. The review includes data from clinical as well as in vitro studies for the period 1998–2017. The search for relevant sources was carried out in the Medline, Cochrane Library, Elibrary and other databases. Results. The analysis of the data showed the presence of synergism and additive activity of polymyxin in combination with carbapenems, rifampicin and azithromycin. However, experimental data showed no direct positive correlation between combination of polymyxim and azithromycin/ rifampicin. In clinical studies, in hospital-acquired pneumonia, including ventilator-associated pneumonia, the clinical response rate of polymyxin B combined with other antibiotics ranged from 38 [%] to 88 [%]. High nephro- and neurotoxicity of poly